Gossamer Bio announces special shareholder meeting via webcast
GOSS•Details of the private placement
The private placement includes an initial $25 million issuance of pre-funded warrants at USD 0.14 per underlying common share.
A second closing targets about USD 125 million upon FDA NDA filing acceptance for seralutinib in PAH, with additional FDA Approval Warrants.
Special shareholder meeting planned for 2026
Gossamer Bio plans a virtual special shareholder meeting in 2026 to seek approval tied to its Aug. 20 private placement.
The vote will cover authorizing common stock issuance from exercises of Pre-Funded Warrants, FDA Approval Warrants, and conversions of Series A-1, A-2, A-3 preferred.
